References
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. doi:10.1056/NEJMoa0708857.
Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101–7. doi:10.1016/j.jhep.2012.02.016.
Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, et al. Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer. Clin Respir J. 2016; doi:10.1111/crj.12605.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oğul, A., Şahin, B., Kuşçu, F. et al. The Importance of Parameters: MPV, MPV/Thrombocyte Ratio and Neutrophil/Lymphocyte Ratio in Sorafenib Treatment Response of Patients with Hepatocellular Cancer. J Gastrointest Canc 48, 286–287 (2017). https://doi.org/10.1007/s12029-017-9970-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-017-9970-5